Zenosense, Inc. (ZENO) Centered on Developing Detection Device to Ward-Off MRSA Cell Activity
Zenosense is looking at developing and marketing a device to be used in healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug.” The company’s findings are grabbing the attention of the medical community as noted in many reputable publications.
ScienceDaily, reporting on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium, stated University of Texas Health Science Center’s international research team has identified a new superbug which has caused an infection in the bloodstream in a patient in Brazil. This case is the first reported bloodstream infection caused by a highly vancomycin-resistant MRSA bacteria. Vancomycin is known to be the least expensive antibiotic used for the treatment of invasive MRSA.
In a U.S. News article it’s reported that Electronic Cigarette vapor appears to increase the virulence of MRSA as well. An abstract from a study conducted by the University of California-San Diego and the VA San Diego Healthcare System claims that MRSA cells exposed to the e-cigarette vapor in the lungs of mice with pneumonia were three times more likely to survive than MRSA cells that were not exposed to the vapor. The lead researcher connected the greater virulence to a change in pH, causing the MRSA bacteria to become defensive and less vulnerable to attack.
In a CBS News story the company cites a study showing MRSA is thriving in homes and hospitals and other healthcare settings. It is being indicated that according to the lead researcher at Columbia University Medical Center, MRSA is now endemic in households. Published April 21, 2014 in Proceedings of the National Academy of Sciences, the findings are based on a study of 161 New York City residents who contracted MRSA between 2009 and 2011. It was determined that people’s residences were housing the MRSA strain USA300, which is the leading cause of community MRSA infections in the U.S.
Zenosense is a detection device development company based in Valencia, Spain. It centers its endeavors on developing, marketing and selling an effective MRSA detector through its licensed technology, for sale to healthcare providers for use in clinical settings.
For more information on the company visit www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com